PNT200
/ GSK
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
December 01, 2020
SPLASH: Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment
(clinicaltrials.gov)
- P3; N=415; Not yet recruiting; Sponsor: POINT Biopharma
Clinical • New P3 trial • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor
1 to 1
Of
1
Go to page
1